# QUILT-3.092 (NCT05618925)

> Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

No report yet. It can be ordered.

- Drugs tested: CD19 t-haNK plus rituximab; CD19 t-haNK plus nogapendekin alfa inbakicept (N-803) plus rituximab
- Indication: relapsed/refractory non-Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05618925
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: ImmunityBio, Inc.
- Conditions: Non Hodgkin's Lymphoma Refractory/Relapsed
- Interventions: N803; CD19t-haNK suspension; Cyclophosphamide; Fludarabine; Rituximab
- Enrollment: 20
- Primary outcome: Primary Outcome Measures

## Indexed commentary on QUILT-3.092 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=quilt-3-092-nct05618925
